EFFICACY AND SAFETY OF MICROPULSE TRANSSCERAL DIODE CYCLOPHOTOCOAGULATION IN PATIENTS WITH GLAUCOMA | ||||
| ALEXMED ePosters | ||||
| Article 33, Volume 2, Issue 2, October 2020, Page 66-66 | ||||
| Document Type: Preliminary preprint short reports of original research | ||||
| DOI: 10.21608/alexpo.2020.50906.1075 | ||||
 View on SCiNiTO | ||||
| Author | ||||
Mohamad Rezk Dawood 
| ||||
| Ophthalmology department, Faculty of Medicine, University of Alexandria, Resident at ministry of health | ||||
| Abstract | ||||
| • Glaucoma is the leading cause of irreversible blindness in the world, with approximately 8.4 million people blind from glaucomaSlowing disease progression and preservation of quality of life are the main goals for glaucoma treatment. • The only applied proven method to treat glaucoma is the reduction of intraocular pressure • Current glaucoma therapies include topical and systemic drugs, laser surgery, invasive glaucoma surgeries. • The new Micropulse Trans scleral Cyclophotocoagulation (MPTSCPC) is a non-incisional, noninvasive LASER treatment for glaucoma The micropulse delivery mode includes "on" and "off" cycles, allowing energy to build up in the targeted pigmented tissues, eventually reaching the coagulative threshold. The adjacent non-pigmented structures have time to " cool off" during the "off " cycle, thus never reaching the coagulative threshold, which minimizes collateral tissue damage Aim of work The aim of this study is to evaluate the efficacy and safety of contact transscleral micropulse diode cyclophotocoagulation in patients with glaucoma. | ||||
| Keywords | ||||
| Micropulse Trans scleral Cyclophotocoagulation (MPTSCPC); Cyclophotocoagulation; Diode laser | ||||
|
Statistics Article View: 116 |
||||
